ArticleFrontiers in oncology2026
Neoadjuvant chemotherapy enabling resection of stage IVA thymoma with myasthenia gravis and systemic lupus erythematosus: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thymomas are rare epithelial tumors of the anterior mediastinum associated with autoimmune disease, particularly myasthenia gravis (MG). The coexistence of thymoma, MG, and systemic lupus erythematosus (SLE) is uncommon and can complicate diagnosis due to overlapping autoimmune manifestations. Management of advanced thymoma is challenging given limited prospective data and an uncertain optimal role for neoadjuvant therapy. Case presentation: A 32-year-old woman with systemic lupus erythematosus (SLE) presented with progressive proximal muscle weakness, diplopia, and dysphagia. Examination and serologic testing confirmed MG with elevated acetylcholine receptor antibodies. Chest computed tomography showed an anterior mediastinal mass (8.7 × 6.0 × 8.8 cm) abutting major mediastinal vessels, including the left superior pulmonary vein, main pulmonary artery trunk, left atrial appendage, and left brachiocephalic vein with concern for vascular invasion, along with pleural drop metastases. CT-guided core needle biopsy demonstrated thymoma, and the disease was staged as clinical stage IVA (cT2N0M1a). She received four cycles of cisplatin, doxorubicin, and cyclophosphamide (CAP) followed by two cycles of carboplatin and paclitaxel. Neoadjuvant therapy led to significant clinical improvement, near-complete resolution of dysphagia and weakness, marked radiographic tumor regression, and disappearance of pleural lesions. She subsequently underwent median sternotomy with extended thymectomy and en bloc resection of involved mediastinal tissues. Final pathology confirmed predominantly type B3 thymoma with negative margins. Postoperative radiotherapy was administered. At latest follow-up, she had complete resolution of MG symptoms and no radiographic evidence of recurrent disease. Conclusion: This case highlights challenges in managing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.